Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors

Circulating tumor cells (CTCs) hold great potential to answer key questions of how non-small cell lung cancer (NSCLC) evolves and develops resistance upon anti-PD-1/PD-L1 treatment. Currently, their clinical utility in NSCLC is compromised by a low detection rate with the established, Food and Drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Janning, Melanie, Kobus, Franca, Babayan, Anna, Wikman, Harriet, Velthaus, Janna-Lisa, Bergmann, Sonja, Schatz, Stefanie, Falk, Markus, Berger, Lars-Arne, Böttcher, Lisa-Marie, Päsler, Sarina, Gorges, Tobias M., O’Flaherty, Linda, Hille, Claudia, Joosse, Simon A., Simon, Ronald, Tiemann, Markus, Bokemeyer, Carsten, Reck, Martin, Riethdorf, Sabine, Pantel, Klaus, Loges, Sonja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627043/
https://www.ncbi.nlm.nih.gov/pubmed/31212989
http://dx.doi.org/10.3390/cancers11060835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627043/
https://www.ncbi.nlm.nih.gov/pubmed/31212989
http://dx.doi.org/10.3390/cancers11060835

Ejemplares similares